Program

In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries of innovation to design an event that works in today’s quickly changing environment. 

In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.

Healthcare Utilization, Employment and Sickness Absence Among Patients with Psoriasis and Psoriatic Arthritis in Sweden: Descriptive Analysis from a Nationwide Register-Based Study

Speaker(s)

Cai Q(1, Teneralli RE2, Peterson S2, Rahman I3, Contre C4, Di Scala L5
1Janssen Global Services LLC., Health Economics & RWE, Titusville, NJ, USA, 2Janssen Global Services, LLC., Horsham, PA, USA, 3SDS Life Science, Stockholm, Sweden, 4Janssen EMEA Medical Affairs, Issy-les-Moulineaux, France, 5Janssen Global Services Health Economics & RWE, Allschwil, BL, Switzerland

OBJECTIVES: Evaluate the annual inpatient admission, outpatient visit, employment status and sickness absence among patients with PsO and PsA in Sweden.

METHODS: Data were obtained from four nationwide population-based registers maintained by the National Board of Health and Welfare in Sweden and linked through unique personal identity numbers. Individuals with ≥ 1 diagnosis of PsO (ICD-10: L40) or PsA (ICD-10: L40.5 or L40 plus one of the following M07.0, M07.1, M07.2, M07.3, M09.0) from 1/1/2001 to 12/30/2017 were selected, respectively. Date of first diagnosis was designated as index date for each cohort. All individuals were followed until death, lost to follow up or the end of the study period.

RESULTS: A total of 199,662 patients with PsO and 43,786 with PsA were evaluated. The mean (±SD) age of patients with PsO was 50.5 (±19.3) years and 51.5 (±15.5) for PsA, with median follow-up of 7.7 years (Q1-Q3: 3.9-12.3) for PsO and 7.96 (Q1-Q3: 4.0-12.6) for PsA. 18% of PsO patients had a PsA diagnosis after the index date and the average time from PsO to PsA was 2.27 (±3.2) years. 20.4% (n=40,694) of PsO patients and 22.9% (n=10,021) of PsA patients had ≥ 1 all-cause inpatient admission during 1-year post-index period. Among patients with ≥ 1 all-cause outpatient services (PsO: n=197,305; PsA: n=43,343), 24.1% and 36.1% of patients had ≥ 5 visits 1-year post-index. Among patients of working age who were in employment (PsO: n=93,513; PsA: n=22,713), 22.2% and 34.0% reported sickness absence within the first calendar year after index date, respectively.

CONCLUSIONS: Patients with PsO or/and PsA incurred substantial resource utilization and imposed considerable work productivity loss to patients, employers, and the society in Sweden. In this descriptive analysis, patients with PsA had higher annual resource utilization and productivity loss than those with PsO.

Code

EE382

Topic

Economic Evaluation

Disease

Systemic Disorders/Conditions